At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
PF-06946860 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
In Brief
A Phase 1 clinical trial evaluating PF-06946860 and Placebo for PF-06946860 for Non-small Cell Lung Cancer and 9 related conditions. Completed, enrolled 18 participants across 33 sites in 2 countries.
Detailed Summary
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMay 2021
Primary CompletionApr 2022
Study CompletionAug 2022
TodayJul 2026
First PostedMar 17, 2021
Enrollment StartMay 11, 2021
Primary CompletionApr 14, 2022
Study CompletionAug 9, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.3 years ago
Interventions
PF-06946860drug
subcutaneous injection
Placebo for PF-06946860drug
subcutaneous injection